JP2017534644A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534644A5 JP2017534644A5 JP2017525007A JP2017525007A JP2017534644A5 JP 2017534644 A5 JP2017534644 A5 JP 2017534644A5 JP 2017525007 A JP2017525007 A JP 2017525007A JP 2017525007 A JP2017525007 A JP 2017525007A JP 2017534644 A5 JP2017534644 A5 JP 2017534644A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 2
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 2
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000005734 heterodimerization reaction Methods 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192524.8 | 2014-11-10 | ||
| EP14192524 | 2014-11-10 | ||
| PCT/EP2015/075876 WO2016075035A1 (en) | 2014-11-10 | 2015-11-06 | Anti-ang2 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020205947A Division JP2021050229A (ja) | 2014-11-10 | 2020-12-11 | 抗ａｎｇ２抗体及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017534644A JP2017534644A (ja) | 2017-11-24 |
| JP2017534644A5 true JP2017534644A5 (cg-RX-API-DMAC7.html) | 2018-12-06 |
Family
ID=51868115
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525007A Pending JP2017534644A (ja) | 2014-11-10 | 2015-11-06 | 抗ａｎｇ２抗体及び使用方法 |
| JP2020205947A Pending JP2021050229A (ja) | 2014-11-10 | 2020-12-11 | 抗ａｎｇ２抗体及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020205947A Pending JP2021050229A (ja) | 2014-11-10 | 2020-12-11 | 抗ａｎｇ２抗体及び使用方法 |
Country Status (14)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| JP6946184B2 (ja) | 2014-11-10 | 2021-10-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| KR20170080584A (ko) | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | 이중특이적 항체 및 안과학에서 이의 사용 방법 |
| EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| JP7074859B2 (ja) * | 2017-12-22 | 2022-05-24 | エフ．ホフマン－ラ ロシュ アーゲー | 疎水性相互作用クロマトグラフィーによる軽鎖誤対合抗体変種の枯渇の方法 |
| KR102497171B1 (ko) | 2018-02-20 | 2023-02-08 | 기초과학연구원 | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 |
| WO2019164219A1 (en) * | 2018-02-20 | 2019-08-29 | Institute For Basic Science | Anti-angiopoietin-2 antibodies and uses thereof |
| JP2023530187A (ja) | 2020-06-22 | 2023-07-13 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 抗ａｎｇ－２抗体とその用途 |
| US20230312698A1 (en) * | 2020-08-07 | 2023-10-05 | Nanjing GenScript Biotech Co., Ltd. | Antibodies against human angiopoietin-2 and uses thereof |
| CA3192239A1 (en) * | 2020-08-19 | 2022-02-24 | Pharmabcine Inc. | Modified antibody and method for manufacturing same |
| CN115772544B (zh) * | 2021-09-06 | 2024-04-26 | 合肥星眸生物科技有限公司 | 抗vegf-a和ang-2的aav载体 |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| CN117820490A (zh) * | 2022-09-28 | 2024-04-05 | 科兴生物制药股份有限公司 | Vegf和ang-2双特异性抗体及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| AU2003208946A1 (en) | 2002-02-28 | 2003-09-16 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| CA2509136C (en) | 2003-01-24 | 2013-10-29 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| WO2005087812A1 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JO2913B1 (en) * | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| CA2727171A1 (en) | 2008-06-06 | 2009-12-10 | Xoma Technology Ltd. | Methods for the treatment of rheumatoid arthritis |
| RU2368359C1 (ru) | 2008-07-22 | 2009-09-27 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Способ лечения возрастной макулярной дегенерации |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| MX2013001267A (es) | 2010-08-13 | 2013-04-10 | Genentech Inc | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. |
| RU2013115927A (ru) | 2010-09-10 | 2014-10-20 | Апексиджен, Инк. | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ |
| CA2830254C (en) * | 2011-03-16 | 2019-09-10 | Amgen Inc. | Fc variants |
| JP6069312B2 (ja) * | 2011-06-29 | 2017-02-01 | アムジェン インコーポレイテッド | 腎細胞癌の治療における生存の予測バイオマーカー |
| EP2867360B1 (en) | 2012-06-28 | 2019-05-08 | Molecular Partners AG | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| US9695233B2 (en) * | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
| CN104661678A (zh) * | 2012-09-28 | 2015-05-27 | 勃林格殷格翰国际有限公司 | 包含双重血管生成素-2/Dll4结合物和抗VEGF-R药剂的药物组合 |
| KR20150060686A (ko) * | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물 |
| BR112015010566A2 (pt) | 2012-11-08 | 2017-07-11 | Clearside Biomedical Inc | métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos |
| EP2917237A1 (en) | 2012-11-09 | 2015-09-16 | Pfizer Inc. | Platelet-derived growth factor b specific antibodies and compositions and uses thereof |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| UA118029C2 (uk) * | 2013-04-29 | 2018-11-12 | Ф. Хоффманн-Ля Рош Аг | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування |
| PE20160753A1 (es) * | 2013-12-20 | 2016-08-01 | Hoffmann La Roche | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 |
| RU2727639C2 (ru) * | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| JP6946184B2 (ja) | 2014-11-10 | 2021-10-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
| KR20170080584A (ko) * | 2014-11-10 | 2017-07-10 | 에프. 호프만-라 로슈 아게 | 이중특이적 항체 및 안과학에서 이의 사용 방법 |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| US20190004048A1 (en) * | 2015-06-26 | 2019-01-03 | Amgen Inc. | Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor |
| US11198726B2 (en) * | 2017-06-02 | 2021-12-14 | Boerhinger Ingelheim International Gmbh | Anti-cancer combination therapy |
-
2015
- 2015-11-06 SG SG11201703458UA patent/SG11201703458UA/en unknown
- 2015-11-06 CN CN201580060787.3A patent/CN107001456A/zh active Pending
- 2015-11-06 MX MX2017005642A patent/MX2017005642A/es unknown
- 2015-11-06 KR KR1020177015610A patent/KR20170082594A/ko not_active Withdrawn
- 2015-11-06 JP JP2017525007A patent/JP2017534644A/ja active Pending
- 2015-11-06 BR BR112017009790A patent/BR112017009790A2/pt not_active Application Discontinuation
- 2015-11-06 EP EP15790575.3A patent/EP3218398A1/en not_active Withdrawn
- 2015-11-06 CA CA2963606A patent/CA2963606A1/en not_active Abandoned
- 2015-11-06 AU AU2015345321A patent/AU2015345321A1/en not_active Abandoned
- 2015-11-06 WO PCT/EP2015/075876 patent/WO2016075035A1/en not_active Ceased
- 2015-11-09 TW TW104136927A patent/TW201630935A/zh unknown
- 2015-11-09 AR ARP150103648A patent/AR102595A1/es unknown
-
2017
- 2017-03-30 IL IL251477A patent/IL251477A0/en unknown
- 2017-05-10 US US15/591,600 patent/US10538585B2/en not_active Expired - Fee Related
-
2020
- 2020-12-11 JP JP2020205947A patent/JP2021050229A/ja active Pending